



Consolidated Statements of Operations
(Amounts in thousands, except per share amounts)
(Unaudited)

	September 27, 2024	December 31, 2024	March 28, 2025	June 27, 2025	September 26, 2025	December 31, 2025	April 3, 2026	July 3, 2026
Revenue	\$ 244,405	\$ 238,060	\$ 233,366	\$ 241,049	\$ 247,836	\$ 258,349	\$ 257,707	\$ 265,807
Cost of revenue	135,190	129,835	129,012	134,303	136,915	145,086	144,129	144,892
Gross profit	109,215	108,225	104,354	106,746	110,921	113,263	113,578	120,915
Operating expenses:								
Research and development and engineering	23,253	25,285	23,238	25,289	24,090	22,867	23,251	23,968
Selling, general and administrative	44,319	43,301	45,596	47,103	51,378	51,582	54,409	59,972
Amortization of purchased intangible assets	6,589	6,548	5,554	6,871	6,928	8,124	5,774	6,415
Restructuring, acquisition, and related costs	2,499	6,384	(2,455)	12,572	6,677	5,858	2,605	12,499
Total operating expenses	76,660	81,518	71,933	91,835	89,073	88,431	86,039	102,854
Operating income	32,555	26,707	32,421	14,911	21,848	24,832	27,539	18,061
Interest income (expense), net	(8,079)	(6,890)	(5,644)	(5,815)	(6,014)	(3,999)	(1,843)	(1,106)
Foreign exchange transaction gains (losses), net	(202)	1,200	(368)	(2,744)	14	908	731	(801)
Other income (expense), net	(49)	(222)	9	(563)	(90)	(64)	(73)	(256)
Income before income taxes	24,225	20,795	26,418	5,789	15,758	21,677	26,354	15,898
Income tax provision (benefit)	5,033	4,331	5,210	1,292	5,105	4,206	5,255	3,357
Net income	\$ 19,192	\$ 16,464	\$ 21,208	\$ 4,497	\$ 10,653	\$ 17,471	\$ 21,099	\$ 12,541
Earnings per common share:								
Basic	\$ 0.53	\$ 0.46	\$ 0.59	\$ 0.12	\$ 0.30	\$ 0.46	\$ 0.52	\$ 0.31
Diluted	\$ 0.53	\$ 0.46	\$ 0.59	\$ 0.12	\$ 0.30	\$ 0.45	\$ 0.51	\$ 0.30
Weighted average common shares outstanding—basic	35,959	35,980	36,024	36,022	35,967	38,237	40,425	41,009
Weighted average common shares outstanding—diluted	36,129	36,148	36,130	36,076	36,040	38,681	41,158	41,164
Adjusted EBITDA (Non-GAAP):								
Net Income (GAAP)	\$ 19,192	\$ 16,464	\$ 21,208	\$ 4,497	\$ 10,653	\$ 17,471	\$ 21,099	\$ 12,541
Interest (income) expense, net	8,079	6,890	5,644	5,815	6,014	3,999	1,843	1,106
Income tax provision	5,033	4,331	5,210	1,292	5,105	4,206	5,255	3,357
Depreciation and amortization	14,155	14,363	13,563	15,581	15,711	17,077	14,160	14,648
Share-based compensation	6,364	4,635	7,100	7,498	6,698	8,242	9,796	9,836
Restructuring, acquisition and related costs	2,491	6,376	(3,106)	12,091	6,156	5,302	2,098	11,438
Inventory related charges associated with a product line closure	-	-	-	65	-	-	-	-
Officer transition costs	1,411	-	-	-	1,137	-	-	-
Planning and design phase of the financial and operation system implementation	-	-	-	1,693	3,519	2,392	2,658	2,204
Costs incurred for insurance recovery claim	-	-	-	324	3,042	2,854	-	3,368
Operational transformation costs	-	-	-	-	-	-	556	797
EU medical device regulation charges	-	-	-	-	-	-	269	378
Other, net	251	(978)	359	3,307	76	(844)	(658)	1,057
Adjusted EBITDA (Non-GAAP)	\$ 56,976	\$ 52,081	\$ 49,978	\$ 52,163	\$ 58,111	\$ 60,699	\$ 57,076	\$ 60,730